Cargando…
Redox Responsive Hyaluronic Acid Nanogels for Treating RHAMM (CD168) Over-expressive Cancer, both Primary and Metastatic Tumors
It remains a substantial challenge to targetedly deliver drug to both primary tumors and metastatic lesions employing a single nanoparticle delivery system. Here aiming at the receptor for hyaluronic acid mediated motility (RHAMM or CD168), a specific receptor for hyaluronic acid (HA), the bioreduct...
Autores principales: | Yang, Chenchen, Li, Cheng, Zhang, Peng, Wu, Wei, Jiang, Xiqun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436523/ https://www.ncbi.nlm.nih.gov/pubmed/28529647 http://dx.doi.org/10.7150/thno.18340 |
Ejemplares similares
-
The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells
por: Willemen, Yannick, et al.
Publicado: (2016) -
Editorial: Interaction Between Hyaluronic Acid and Its Receptors (CD44, RHAMM) Regulates the Activity of Inflammation and Cancer
por: Naor, David
Publicado: (2016) -
Redox-Responsive Hyaluronic Acid-Based Nanogels for
the Topical Delivery of the Visual Chromophore to Retinal Photoreceptors
por: Laradji, Amine M., et al.
Publicado: (2021) -
Tumor-Tissue Expression of the Hyaluronic Acid Receptor RHAMM Predicts Histological Transformation in Follicular Lymphoma Patients
por: Enemark, Marie Beck, et al.
Publicado: (2022) -
Uncovering the dual role of RHAMM as an HA receptor and a regulator of CD44 expression in RHAMM-expressing mesenchymal progenitor cells
por: Veiseh, Mandana, et al.
Publicado: (2015)